滨州医学院学报Issue(4)：260-262,3.
冠心病合并糖尿病患者瑞舒伐他汀联合非诺贝特治疗的疗效与安全性
The effect and security of combined treatment of rosuvastatin and fenofibrate in coronary heart disease patients with diabetes mellitus
赵云慧 1刘相星 1庄见群 1孔祥海 1王跃明 1李原 1孙运强1
作者信息
- 1. 日照市东港区人民医院 日照 276800
- 折叠
摘要
Abstract
Objective To observe the effect and security of combined treatment of rosuvastatin and fenofibrate in coronary heart disease patients with diabetes mellitus .Methods 94 hospitalized cases of coronary heart disease with type 2 diabetes com‐bined with serum high triglyceride (TG) levels and /or reduced high density lipoprotein cholesterol (HDL‐C) were selected and randomly divided into two groups on the basis of conventional treatment :control group (47 cases) ,given rosuvastatin 10 mg every night ;the treatment group (47 cases) ,given rosuvastatin 10 mg every night ,micronized fenofibrate 200 mg ,1 times a day .The level of total cholesterol (TC) ,TG ,low density lipoprotein cholesterol (LDL‐C) and HDL‐C were respectively detec‐ted in before treatment ,4 weeks and 8 weeks after treatment .Adverse reactions and clinical events were recorded .Results Af‐ter 4 weeks of treatment ,the levels of TC ,TG ,LDL‐C in two groups were significantly lower than that before treatment .After 8 weeks of treatment ,decreased significantly(P<0.05) .The drop of treatment group were higher than that of control group in 8th weekend (P< 0.05) .HDL‐C increased in two groups after treatment .HDL‐C obviously increased after 8 weeks (P<0.05) ,by 21.7% in control group ,23.9% in the treatment group ,but there is no statistical difference in two groups ( P>0.05) .After 8 weeks ,LDL‐C ,TG ,HDL‐C ,3 blood lipids in the treatment group are standard .Non HDL‐C standard rate were significantly higher than that of the control group (P<0.05) .During the treatment ,there were no serious adverse events in two groups .Conclusion The combined treatment of rosuvastatin and fenofibrate on coronary heart disease with type 2 diabetes with high triglyceride (TG) levels and/or reduced HDL‐C help blood lipid comprehensive standards ,and has good security .关键词
冠状动脉疾病/2型糖尿病/混合型高脂血症/降血脂药Key words
coronary artery disease/type 2 diabetes/mixed demia/antilipemic agents分类
医药卫生引用本文复制引用
赵云慧,刘相星,庄见群,孔祥海,王跃明,李原,孙运强..冠心病合并糖尿病患者瑞舒伐他汀联合非诺贝特治疗的疗效与安全性[J].滨州医学院学报,2015,(4):260-262,3.
